Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

MLA

Penalver, Francisco-Javier, et al. Response-Adapted Treatment with Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients with Relapsed or Refractory Follicular Lymphoma after First-Line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. Jan. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b016266cc0c27999365889288230dbc8&authtype=sso&custid=ns315887.

APA

Penalver, F.-J., Marquez, J.-A., Duran, S., Giraldo, P., Martin, A., Montalban, C., Sancho, J.-M., Ramirez, M.-J., Terol, M.-J., Capote, F.-J., Gutierrez, A., Sanchez, B., Lopez, A., Salar, A., Rodriguez-Caravaca, G., Canales, M., Caballero, M.-D., Bello Lopez, J. L., Carbonell, F., … GELTAMO Spanish Lymphoma Cooperati. (2019). Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Chicago

Penalver, Francisco-Javier, Jose-Antonio Marquez, Soledad Duran, Pilar Giraldo, Alejandro Martin, Carlos Montalban, Juan-Manuel Sancho, et al. 2019. “Response-Adapted Treatment with Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients with Relapsed or Refractory Follicular Lymphoma after First-Line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b016266cc0c27999365889288230dbc8&authtype=sso&custid=ns315887.